Intranasal Oxytocin and Learning in Autism

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Autism Spectrum Disorders
Interventions
DRUG

Intranasal Oxytocin (Trade name: Syntocinon)

This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.

Trial Locations (1)

19104

The Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Robert Schultz

OTHER

NCT01417026 - Intranasal Oxytocin and Learning in Autism | Biotech Hunter | Biotech Hunter